BRAF and melanoma: Growth inhibition of NRASQ61R melanomas (as well as BRAF-mutant melanomas) was also achieved by administering the protein phosphatase 2A (PP2A) inhibitor, a phendione derivative, or through depletion of PP2A catalytic subunits [26].